Efficacy and safety of empagliflozin in glycogen storage disease type Ib: Data from an international questionnaire

Empagliflozin ameliorated neutropenia in a girl with glycogen storage disease Ib

(2021) Masamitsu Mikami et al.   PEDIATRICS INTERNATIONAL

Treating neutropenia and neutrophil dysfunction in glycogen storage disease IB with an SGLT2-inhibitor

(2020) Saskia B Wortmann et al.   BLOOD

Improved inflammatory bowel disease, wound healing and normal oxidative burst under treatment with empagliflozin in glycogen storage disease type Ib

(2020) Sarah C. Grünert et al.   Orphanet Journal of Rare Diseases

Failure to eliminate a phosphorylated glucose analog leads to neutropenia in patients with G6PT and G6PC3 deficiency

(2019) Maria Veiga-da-Cunha et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Neutropenia in glycogen storage disease Ib

(2018) David C. Dale et al.   CURRENT OPINION IN HEMATOLOGY

Neutrophil heterogeneity: implications for homeostasis and pathogenesis

(2016) C. Silvestre-Roig et al.   BLOOD

Model analysis of effect of canagliflozin (Invokana), a sodium–glucose cotransporter 2 inhibitor, to alter plasma 1,5-anhydroglucitol

(2016) Danielle Fortuna et al.   CLINICA CHIMICA ACTA

World Medical Association Declaration of Helsinki

(2013)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION